SciELO - Scientific Electronic Library Online

 
vol.65 issue6Clinical research on lumbar oblique-pulling manipulation in combination with sling exercise therapy for patients with chronic nonspecific low back painPathological fracture after radiotherapy: systematic review of literature author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Revista da Associação Médica Brasileira

Print version ISSN 0104-4230On-line version ISSN 1806-9282

Abstract

VEIGA, Glaucia Luciano da et al. The role of Survivin as a biomarker and potential prognostic factor for breast cancer. Rev. Assoc. Med. Bras. [online]. 2019, vol.65, n.6, pp.893-901.  Epub July 22, 2019. ISSN 0104-4230.  https://doi.org/10.1590/1806-9282.65.6.893.

Breast cancer (BC) is one of the primary health problems worldwide. As the most common cancer in women in the world and in Brasil, behind only non-melanoma skin cancer, this neoplasm corresponds to approximately 28% of new cases per year in the country. BC also affects men, although the incidence corresponds to only 1% of total cases. Currently, most of the chemotherapeutic agents used in BC treatment are extremely toxic and cause long-term side effects. There is also a need to obtain earlier diagnoses, more accurate prognoses and make new therapies available that are more selective and effective in order to improve the current scenario. Therefore, this work sought to evaluate the importance of the biomarker survivin (Sur) in relation to BC, through the detailing of the role of Sur as a biomarker, the correlation between this protein and the prognosis of BC patients, and a summary of therapeutic strategies that target Sur for the development of new anticancer therapies.

Keywords : Breast Neoplasms; Prognosis; Neoplasm Metastasis; Inhibitor of Apoptosis Proteins.

        · abstract in Portuguese     · text in English     · English ( pdf )